How many difficulties are there on the way to the Rongchang Biotech Plan's fixed increase of over 2 billion yuan

“Investor Network” Cai Jun Rongchang Biotech (688331.sh, hereinafter referred to as the “Company”) has reached another critical point. At the end of March, the company announced a fixed increase plan. It plans to raise up to 2.55 billion yuan, all of which will be used for “new drug research and development projects”, including RC18, RC48, RC28, RC88, RC148, and RC198. Around the same time, the company also released its 2023 annual report. Up to now, the company's core marketed products include taitacip, verdicitumab, etc. During the reporting period, the company's revenue increased by 40.26% year on year, net profit to mother - 1.51 billion yuan, loss

China Investors07:31

CCB International: Maintaining Rongchang Biotech's (09995.HK) “Outperform the Market” rating and raising the target price to HK$34

CCB International released a research report stating that while maintaining Rongchang Biotech (09995.HK)'s “outperforming the market” rating, the target price was raised by 30.8% from HK$26 to HK$34. The company's 2023 results were basically in line with expectations, and the fourth quarter of 2023 results exceeded CCB's expectations. Overall net losses for the fourth quarter of 2023 and 2023 reached 1.5 billion yuan (same below) and 481 million yuan respectively. Excluding equity incentive costs, net losses would be $1.4 billion and $365 million respectively, which is less than anticipated.

Zhitong FinanceApr 12 15:19

Changes in Hong Kong stocks | Rongchang Biotech (09995.HK) rose more than 9% in the afternoon, rapid release of core products, and the company has many catalysts this year

Rongchang Biotech (09995.HK) rose more than 9% in the afternoon. As of press release, it rose 7.9% to HK$33.45, with a turnover of HK$68,8303 million.

Zhitong FinanceApr 11 13:53

Statistics on changes in the share of Zhitong Hong Kong Stock Connect | April 11

According to data disclosed on April 10, 2024, CNOOC Oilfield Services (02883.HK), Southern Hang Seng Technology (03033.HK), and Zhonglian Heavy Industries (01157.HK) Hong Kong Stock Connect held the largest share gains, increasing by 1.41%, 0.87%, and 0.68% respectively; Saisheng Pharmaceutical (06600.HK), Oriental Selection (01797.HK), and Rongchang Biotech (09995.HK) Hong Kong Stock Connect shares decreased the most, with decreases of -0.77% and -0.71%, respectively -0.60%

Zhitong FinanceApr 11 08:35

Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction

① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.

cls.cnApr 10 22:19

Beijing has brought great benefits to innovative drugs!

In the middle of the night of April 7, the Beijing Municipal Medical Security Administration suddenly issued a “Notice on Public Consultation on the “Certain Measures to Support the High-Quality Development of Innovative Medicines by 9 Departments Including the Beijing Municipal Medical Security Administration (2024) (Draft for Comments)”. The public submission period for this consultation draft is only 3 working days. The first section of the clinical study clearly proposed reducing the overall time required to start a clinical trial to 28 weeks.

券商中國Apr 8 15:52